The introduction of GLP-1 receptor agonists has transformed the treatment of type 2 diabetes and obesity, helping millions achieve better blood sugar control and meaningful weight loss. Among the latest advancements is tirzepatide, a first-in-class medication that has demonstrated remarkable results in clinical trials. While several GLP-1 medications are available today, many healthcare professionals consider tirzepatide one of the most effective options for eligible patients due to its dual-action mechanism and impressive clinical outcomes.